Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2002

View Archived Issues

New therapeutic approaches for renal cell carcinoma presented at the AUA meeting

Azole CRF1 antagonists presented by BMS

5-HT receptor ligands and their use in sleep disorders, etc.

Boehringer Ingelheim patents dual ligands of 5-HT and D4 receptors

Novel antiandrogens in the Yamanouchi pipeline

BMS patent describes DNA topoisomerase I inhibitors

Endocannabinoid receptor modulators identified by Lilly research team

Antifungal thiazolidinones discovered at Oxford GlycoSciences

Early clinical data for DRF-1042 presented at ASCO

Clinical data on one of Igeneon's cancer vaccine candidates discussed at ASCO meeting

Potent inhibitor of Jak family protein tyrosine kinases discovered at Merck

Orally bioavailable peptidomimetic rhinoviral protease inhibitor

Investigational HIV protease inhibitor submitted for review in Europe by BMS

Dual inhibition of FPP synthetase and IPP isomerase displayed by a new bisphosphonate

Phase I results support further development of ABX-EGF for cancer

LymphoRad targets B-cells and B-cell tumors and exerts antitumor activity in preclinical studies

ThGRF improves sleep parameters and daytime vigilance in insomnia

Cathepsin S inhibitors with potential application in MS

Single-dose palonosetron provides prolonged relief from CINV

MLN-518 enters phase I in AML

Second phase II trial for GVAX pancreatic cancer vaccine

Platelet-derived growth factor evaluated in periodontal disease

Adenosine Therapeutics receives grant to develop A2A adenosine receptor agonists for sepsis

Patient enrollment completed in phase II trial of BioBypass in peripheral vascular disease

Moli-1901 enters phase II development in cystic fibrosis

Start of phase I trial of NOX-700 in type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...